Revlimid Capsules Special Drug Use-results Survey (in Patients With Newly-diagnosed Multiple Myeloma [NDMM])
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 08 Mar 2018
At a glance
- Drugs Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 01 Mar 2018 Planned End Date changed from 1 Aug 2021 to 21 Aug 2021.
- 01 Mar 2018 Planned primary completion date changed from 1 Aug 2021 to 21 Aug 2021.
- 01 Mar 2018 Status changed from recruiting to active, no longer recruiting.